Combination therapy in diabetic neuropathy

T. Várkonyi, L. Czupryniak, I. Gurieva, B. N. Mankovsky, O. Schnell, V. Spallone, S. Tesfaye, I. A. Veresiu, D. Ziegler, M. Erbach, R. Garcia-Verdugo, P. Kempler

Research output: Contribution to journalArticle

Abstract

A high percentage of diabetic patients develop peripheral neuropathy with more than 10% suffering from severe symptoms. Therapeutic alternatives for diabetic sensorimotor polyneuropathy (DSPN) have so far involved pathogenesis-oriented or symptomatic treatments. These two therapeutic approaches differ in their effects: the former aims to reverse, halt or delay progression of neuropathic damage, while the latter aims to relieve neuropathic pain and its associated secondary consequences without impact on the underlying neuropathic process. Most guidelines recommend symptomatic treatments to alleviate the complaints associated with DSPN.Tricyclic antidepressants, Serotoninnoradrenaline reuptake inhibitors, and α2-δ ligands are frequently mentioned as first-line drugs for painful diabetic peripheral neuropathy. However, new evidence points to pathogenesis-oriented treatments based on alpha-lipoic acid or benfotiamine as promising therapeutic alternatives to classical purely symptomatic treatments. A few new trials have reported an advantage of combination therapies versus single-drug administration, but the limited extent of studies on specific combinations together with design flaws in these studies have caused reluctance in recommending combination therapy as a first treatment option in guidelines. However, combination therapy stands as a powerful instrument for DSPN treatment based on the positive evidence accumulated and the otherwise common use of multidrug treatments in clinical diabetic neuropathy.

Original languageEnglish
Pages (from-to)163-168
Number of pages6
JournalDiabetes, Stoffwechsel und Herz
Volume25
Issue number3
Publication statusPublished - Jun 1 2016

Fingerprint

Diabetic Neuropathies
Therapeutics
Peripheral Nervous System Diseases
Guidelines
Thioctic Acid
Tricyclic Antidepressive Agents
Neuralgia
Pharmaceutical Preparations

Keywords

  • Combination therapy
  • Diabetic neuropathy
  • Neuropathic pain
  • Pathogenesis-oriented treatment
  • Symptomatic treatment

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Várkonyi, T., Czupryniak, L., Gurieva, I., Mankovsky, B. N., Schnell, O., Spallone, V., ... Kempler, P. (2016). Combination therapy in diabetic neuropathy. Diabetes, Stoffwechsel und Herz, 25(3), 163-168.

Combination therapy in diabetic neuropathy. / Várkonyi, T.; Czupryniak, L.; Gurieva, I.; Mankovsky, B. N.; Schnell, O.; Spallone, V.; Tesfaye, S.; Veresiu, I. A.; Ziegler, D.; Erbach, M.; Garcia-Verdugo, R.; Kempler, P.

In: Diabetes, Stoffwechsel und Herz, Vol. 25, No. 3, 01.06.2016, p. 163-168.

Research output: Contribution to journalArticle

Várkonyi, T, Czupryniak, L, Gurieva, I, Mankovsky, BN, Schnell, O, Spallone, V, Tesfaye, S, Veresiu, IA, Ziegler, D, Erbach, M, Garcia-Verdugo, R & Kempler, P 2016, 'Combination therapy in diabetic neuropathy', Diabetes, Stoffwechsel und Herz, vol. 25, no. 3, pp. 163-168.
Várkonyi T, Czupryniak L, Gurieva I, Mankovsky BN, Schnell O, Spallone V et al. Combination therapy in diabetic neuropathy. Diabetes, Stoffwechsel und Herz. 2016 Jun 1;25(3):163-168.
Várkonyi, T. ; Czupryniak, L. ; Gurieva, I. ; Mankovsky, B. N. ; Schnell, O. ; Spallone, V. ; Tesfaye, S. ; Veresiu, I. A. ; Ziegler, D. ; Erbach, M. ; Garcia-Verdugo, R. ; Kempler, P. / Combination therapy in diabetic neuropathy. In: Diabetes, Stoffwechsel und Herz. 2016 ; Vol. 25, No. 3. pp. 163-168.
@article{5830e058f465425aa129a36518aaf054,
title = "Combination therapy in diabetic neuropathy",
abstract = "A high percentage of diabetic patients develop peripheral neuropathy with more than 10{\%} suffering from severe symptoms. Therapeutic alternatives for diabetic sensorimotor polyneuropathy (DSPN) have so far involved pathogenesis-oriented or symptomatic treatments. These two therapeutic approaches differ in their effects: the former aims to reverse, halt or delay progression of neuropathic damage, while the latter aims to relieve neuropathic pain and its associated secondary consequences without impact on the underlying neuropathic process. Most guidelines recommend symptomatic treatments to alleviate the complaints associated with DSPN.Tricyclic antidepressants, Serotoninnoradrenaline reuptake inhibitors, and α2-δ ligands are frequently mentioned as first-line drugs for painful diabetic peripheral neuropathy. However, new evidence points to pathogenesis-oriented treatments based on alpha-lipoic acid or benfotiamine as promising therapeutic alternatives to classical purely symptomatic treatments. A few new trials have reported an advantage of combination therapies versus single-drug administration, but the limited extent of studies on specific combinations together with design flaws in these studies have caused reluctance in recommending combination therapy as a first treatment option in guidelines. However, combination therapy stands as a powerful instrument for DSPN treatment based on the positive evidence accumulated and the otherwise common use of multidrug treatments in clinical diabetic neuropathy.",
keywords = "Combination therapy, Diabetic neuropathy, Neuropathic pain, Pathogenesis-oriented treatment, Symptomatic treatment",
author = "T. V{\'a}rkonyi and L. Czupryniak and I. Gurieva and Mankovsky, {B. N.} and O. Schnell and V. Spallone and S. Tesfaye and Veresiu, {I. A.} and D. Ziegler and M. Erbach and R. Garcia-Verdugo and P. Kempler",
year = "2016",
month = "6",
day = "1",
language = "English",
volume = "25",
pages = "163--168",
journal = "Diabetes und Stoffwechsel",
issn = "1861-7603",
publisher = "Verlag Kirchheim and Co. GmbH",
number = "3",

}

TY - JOUR

T1 - Combination therapy in diabetic neuropathy

AU - Várkonyi, T.

AU - Czupryniak, L.

AU - Gurieva, I.

AU - Mankovsky, B. N.

AU - Schnell, O.

AU - Spallone, V.

AU - Tesfaye, S.

AU - Veresiu, I. A.

AU - Ziegler, D.

AU - Erbach, M.

AU - Garcia-Verdugo, R.

AU - Kempler, P.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - A high percentage of diabetic patients develop peripheral neuropathy with more than 10% suffering from severe symptoms. Therapeutic alternatives for diabetic sensorimotor polyneuropathy (DSPN) have so far involved pathogenesis-oriented or symptomatic treatments. These two therapeutic approaches differ in their effects: the former aims to reverse, halt or delay progression of neuropathic damage, while the latter aims to relieve neuropathic pain and its associated secondary consequences without impact on the underlying neuropathic process. Most guidelines recommend symptomatic treatments to alleviate the complaints associated with DSPN.Tricyclic antidepressants, Serotoninnoradrenaline reuptake inhibitors, and α2-δ ligands are frequently mentioned as first-line drugs for painful diabetic peripheral neuropathy. However, new evidence points to pathogenesis-oriented treatments based on alpha-lipoic acid or benfotiamine as promising therapeutic alternatives to classical purely symptomatic treatments. A few new trials have reported an advantage of combination therapies versus single-drug administration, but the limited extent of studies on specific combinations together with design flaws in these studies have caused reluctance in recommending combination therapy as a first treatment option in guidelines. However, combination therapy stands as a powerful instrument for DSPN treatment based on the positive evidence accumulated and the otherwise common use of multidrug treatments in clinical diabetic neuropathy.

AB - A high percentage of diabetic patients develop peripheral neuropathy with more than 10% suffering from severe symptoms. Therapeutic alternatives for diabetic sensorimotor polyneuropathy (DSPN) have so far involved pathogenesis-oriented or symptomatic treatments. These two therapeutic approaches differ in their effects: the former aims to reverse, halt or delay progression of neuropathic damage, while the latter aims to relieve neuropathic pain and its associated secondary consequences without impact on the underlying neuropathic process. Most guidelines recommend symptomatic treatments to alleviate the complaints associated with DSPN.Tricyclic antidepressants, Serotoninnoradrenaline reuptake inhibitors, and α2-δ ligands are frequently mentioned as first-line drugs for painful diabetic peripheral neuropathy. However, new evidence points to pathogenesis-oriented treatments based on alpha-lipoic acid or benfotiamine as promising therapeutic alternatives to classical purely symptomatic treatments. A few new trials have reported an advantage of combination therapies versus single-drug administration, but the limited extent of studies on specific combinations together with design flaws in these studies have caused reluctance in recommending combination therapy as a first treatment option in guidelines. However, combination therapy stands as a powerful instrument for DSPN treatment based on the positive evidence accumulated and the otherwise common use of multidrug treatments in clinical diabetic neuropathy.

KW - Combination therapy

KW - Diabetic neuropathy

KW - Neuropathic pain

KW - Pathogenesis-oriented treatment

KW - Symptomatic treatment

UR - http://www.scopus.com/inward/record.url?scp=85018698298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018698298&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85018698298

VL - 25

SP - 163

EP - 168

JO - Diabetes und Stoffwechsel

JF - Diabetes und Stoffwechsel

SN - 1861-7603

IS - 3

ER -